Velaresol
| Code | Size | Price |
|---|
| TAR-T35044-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T35044-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Velaresol (BW12C, BW12C79) is an oxygenated hemoglobin stabilizer that, in addition to stabilizing oxygenated hemoglobin, protects sickle cells from calcium-mediated dehydration.
CAS:
77858-21-0
Formula:
C12H14O5
Molecular Weight:
238.239
Purity:
0.98
SMILES:
OC(=O)CCCCOc1cccc(O)c1C=O
References
Gibson JS, Khan A, Speake PF, Ellory JC. O2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79. FASEB J. 2001 Mar;15(3):823-32. PubMed PMID: 11259401.
Trudel M, De Paepe ME, Chr?tien N, Saadane N, Jacmain J, Sorette M, Hoang T, Beuzard Y. Sickle cell disease of transgenic SAD mice. Blood. 1994 Nov 1;84(9):3189-97. PubMed PMID: 7949191.
Propper DJ, Levitt NC, O'Byrne K, Braybrooke JP, Talbot DC, Ganesan TS, Thompson CH, Rajagopalan B, Littlewood TJ, Dixon RM, Harris AL. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer. 2000 Jun;82(11):1776-82. PubMed PMID: 10839290; PubMed Central PMCID: PMC2363221.
Philip PA, Thompson CH, Carmichael J, Rea D, Mitchell K, Taylor DJ, Stuart NS, Dennis I, Rajagopalan B, Ganesan T, et al. A phase I study of the left-shifting agent BW12C79 plus mitomycin C and the effect on the skeletal muscle metabolism using 31P magnetic resonance spectroscopy. Cancer Res. 1993 Dec 1;53(23):5649-53. PubMed PMID: 8242619.